Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

disease awareness campaign

- PMLiVE

J&J’s Tremfya approved by FDA for children with plaque psoriasis and psoriatic arthritis

The drug is the first IL-23 inhibitor approved for children from the age of six

- PMLiVE

North East and North Cumbria NHS rolls out digital health platform to combat chronic kidney disease, affecting 1 in 10 UK adults

In a significant step towards tackling one of the UK’s most underdiagnosed conditions, North East and North Cumbria Integrated Care Board (ICB) has adopted the Healthinote digital health platform, providing...

Healthinote (by Cognitant)

- PMLiVE

Bridging the gap in personalised digital support: My Stroke Companion

To empower stroke survivors to engage with their care, Cognitant, in partnership with University College London Hospitals (UCLH), identified a need for a new digital health companion that can support...

Healthinote (by Cognitant)

- PMLiVE

Kidney Research UK invests in Healthinote patient education platform which could support >15m people with long term health conditions

Kidney Research UK, the leading charity dedicated to kidney health, has made a significant investment in Cognitant Group Ltd, a leading provider of digital education and support tools to improve...

Healthinote (by Cognitant)

- PMLiVE

Health literacy & the creation of shared decision aids for patients with cancer

In this blog, Gini Melesi, Head of Transformation, East of England Cancer Alliance, & Diane Whitney, Head of Brachytherapy Physics, Cambridge University Hospitals NHS Foundation Trust, explore the relationship between...

Healthinote (by Cognitant)

- PMLiVE

FDA approves new presentation of Celltrion’s SteQeyma for paediatric psoriasis

The Stelara biosimilar now offers all dosage forms and strengths of its reference product

- PMLiVE

LEO and Reig Jofre partner to improve access to psoriasis therapy in Europe

Approximately 125 million people worldwide are affected by some form of the inflammatory condition

- PMLiVE

Bristol Myers Squibb shares five-year results for Sotyktu in plaque psoriasis

Plaque psoriasis affects up to 90% of patients with the immune-mediated disease

- PMLiVE

Bristol Myers Squibb’s Sotyktu shows promise in phase 3 psoriatic arthritis trials

The immune-mediated disease affects approximately 30% of people living with psoriasis

- PMLiVE

AbbVie to expand immunology pipeline with $200m Nimble Therapeutics acquisition

The deal includes an IL23R inhibitor in preclinical development for psoriasis and inflammatory bowel disease

- PMLiVE

Johnson & Johnson’s Tremfya shows promise in ‘special site’ plaque psoriasis

The immune-mediated disease affects more than 125 million people worldwide

- PMLiVE

Bristol Myers Squibb announces positive data for Sotyktu in moderate-to-severe psoriasis

At least 100 million people worldwide are affected by the immune-mediated disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links